Alumis stock slides after envudeucitinib misses lupus trial goal
Alumis shares were pacing for a worst day on record after the company said its lupus drug candidate, envudeucitinib, failed to meet the main goal in a mid-stage trial.
By Mackenzie TatananniAlumis shares were pacing toward their worst day on record Tuesday after the biotech said its lupus drug candidate, envudeucitinib, failed to meet the main goal of a mid-stage trial.Researchers were probing the oral treatment's efficacy in patients with moderate-to-severe syst…